These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 28985763)

  • 1. Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage.
    Kulcsár PI; Tálas A; Huszár K; Ligeti Z; Tóth E; Weinhardt N; Fodor E; Welker E
    Genome Biol; 2017 Oct; 18(1):190. PubMed ID: 28985763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perfectly matched 20-nucleotide guide RNA sequences enable robust genome editing using high-fidelity SpCas9 nucleases.
    Zhang D; Zhang H; Li T; Chen K; Qiu JL; Gao C
    Genome Biol; 2017 Oct; 18(1):191. PubMed ID: 29020979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.
    Kleinstiver BP; Pattanayak V; Prew MS; Tsai SQ; Nguyen NT; Zheng Z; Joung JK
    Nature; 2016 Jan; 529(7587):490-5. PubMed ID: 26735016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy.
    Chen JS; Dagdas YS; Kleinstiver BP; Welch MM; Sousa AA; Harrington LB; Sternberg SH; Joung JK; Yildiz A; Doudna JA
    Nature; 2017 Oct; 550(7676):407-410. PubMed ID: 28931002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blackjack mutations improve the on-target activities of increased fidelity variants of SpCas9 with 5'G-extended sgRNAs.
    Kulcsár PI; Tálas A; Tóth E; Nyeste A; Ligeti Z; Welker Z; Welker E
    Nat Commun; 2020 Mar; 11(1):1223. PubMed ID: 32144253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of the sequence-specific cleavage activity of Cas9 variants.
    Kim N; Kim HK; Lee S; Seo JH; Choi JW; Park J; Min S; Yoon S; Cho SR; Kim HH
    Nat Biotechnol; 2020 Nov; 38(11):1328-1336. PubMed ID: 32514125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cpf1 nucleases demonstrate robust activity to induce DNA modification by exploiting homology directed repair pathways in mammalian cells.
    Tóth E; Weinhardt N; Bencsura P; Huszár K; Kulcsár PI; Tálas A; Fodor E; Welker E
    Biol Direct; 2016 Sep; 11():46. PubMed ID: 27630115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationally engineered Cas9 nucleases with improved specificity.
    Slaymaker IM; Gao L; Zetsche B; Scott DA; Yan WX; Zhang F
    Science; 2016 Jan; 351(6268):84-8. PubMed ID: 26628643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Massively parallel kinetic profiling of natural and engineered CRISPR nucleases.
    Jones SK; Hawkins JA; Johnson NV; Jung C; Hu K; Rybarski JR; Chen JS; Doudna JA; Press WH; Finkelstein IJ
    Nat Biotechnol; 2021 Jan; 39(1):84-93. PubMed ID: 32895548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boosting activity of high-fidelity CRISPR/Cas9 variants using a tRNA
    He X; Wang Y; Yang F; Wang B; Xie H; Gu L; Zhao T; Liu X; Zhang D; Ren Q; Liu X; Liu Y; Gao C; Gu F
    J Biol Chem; 2019 Jun; 294(23):9308-9315. PubMed ID: 31010827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cleavage rule for selection of increased-fidelity SpCas9 variants with high efficiency and no detectable off-targets.
    Kulcsár PI; Tálas A; Ligeti Z; Tóth E; Rakvács Z; Bartos Z; Krausz SL; Welker Á; Végi VL; Huszár K; Welker E
    Nat Commun; 2023 Sep; 14(1):5746. PubMed ID: 37717069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A kinetic model predicts SpCas9 activity, improves off-target classification, and reveals the physical basis of targeting fidelity.
    Eslami-Mossallam B; Klein M; Smagt CVD; Sanden KVD; Jones SK; Hawkins JA; Finkelstein IJ; Depken M
    Nat Commun; 2022 Mar; 13(1):1367. PubMed ID: 35292641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A method for characterizing Cas9 variants via a one-million target sequence library of self-targeting sgRNAs.
    Tálas A; Huszár K; Kulcsár PI; Varga JK; Varga É; Tóth E; Welker Z; Erdős G; Pach PF; Welker Á; Györgypál Z; Tusnády GE; Welker E
    Nucleic Acids Res; 2021 Apr; 49(6):e31. PubMed ID: 33450024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic in vitro specificity profiling reveals nicking defects in natural and engineered CRISPR-Cas9 variants.
    Murugan K; Suresh SK; Seetharam AS; Severin AJ; Sashital DG
    Nucleic Acids Res; 2021 Apr; 49(7):4037-4053. PubMed ID: 33744974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SuperFi-Cas9 exhibits remarkable fidelity but severely reduced activity yet works effectively with ABE8e.
    Kulcsár PI; Tálas A; Ligeti Z; Krausz SL; Welker E
    Nat Commun; 2022 Nov; 13(1):6858. PubMed ID: 36369279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered CRISPR/Cas9 enzymes improve discrimination by slowing DNA cleavage to allow release of off-target DNA.
    Liu MS; Gong S; Yu HH; Jung K; Johnson KA; Taylor DW
    Nat Commun; 2020 Jul; 11(1):3576. PubMed ID: 32681021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deleting specific residues from the HNH linkers creates a CRISPR-SpCas9 variant with high fidelity and efficiency.
    Wang G; Wang C; Chu T; Wu X; Anderson CM; Huang D; Li J
    J Biotechnol; 2023 May; 368():42-52. PubMed ID: 37116617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells.
    Kleinstiver BP; Tsai SQ; Prew MS; Nguyen NT; Welch MM; Lopez JM; McCaw ZR; Aryee MJ; Joung JK
    Nat Biotechnol; 2016 Aug; 34(8):869-74. PubMed ID: 27347757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shortening the sgRNA-DNA interface enables SpCas9 and eSpCas9(1.1) to nick the target DNA strand.
    Fan R; Chai Z; Xing S; Chen K; Qiu F; Chai T; Qiu JL; Zhang Z; Zhang H; Gao C
    Sci China Life Sci; 2020 Nov; 63(11):1619-1630. PubMed ID: 32592086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SMOOT libraries and phage-induced directed evolution of Cas9 to engineer reduced off-target activity.
    Cerchione D; Loveluck K; Tillotson EL; Harbinski F; DaSilva J; Kelley CP; Keston-Smith E; Fernandez CA; Myer VE; Jayaram H; Steinberg BE
    PLoS One; 2020; 15(4):e0231716. PubMed ID: 32298334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.